Amarin stock slips on solo strategy to launch fish oil drug

The future of Amarin ($AMRN) and its fish oil product Vascepa got a little more slippery Thursday. The Irish company said it had obtained $100 million in private financing to move forward with the drug come what may. It will hire up to 300 sales reps to prepare to launch the omega-3 product in the U.S. early next year. Then it will see whether it will find marriage, a marketing partner or go it alone with the drug, which the FDA approved in July but the company has not yet gotten off the ground. It was looking for the FDA to designate it a New Chemical Entity (NCE), which would give the company two more years of exclusivity, but the agency has delayed that decision several times. Meanwhile, Amarin's fortunes have been sinking. Its shares were off 19% to $9.67 as of 10:50 a.m. ET this morning. Article


Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.